1 **Alteration of menaquinone isoprenoid chain length and antibiotic sensitivity by single**
2 **amino acid substitution in HepT**

3 **Running Title: HepT in MK biosynthesis and antibiotic sensitivity**

4 Suresh Panthee^{1,§}, Atmika Paudel^{1,§}, Hiroshi Hamamoto¹, Anne-Catrin Uhlemann², and
5 Kazuhisa Sekimizu^{1,*}

6 ¹ Teikyo University Institute of Medical Mycology, Otsuka 359, Hachioji, Tokyo 192-0395,
7 Japan

8 ² Department of Medicine, Columbia University Medical Center, New York, New York,
9 USA

10 § These authors contributed equally to this work.

11 * Correspondence and requests for materials should be addressed to K.S. email:
12 sekimizu@main.teikyo-u.ac.jp

13

14

15

16 **Abstract**

17 **Objectives:** *Staphylococcus aureus* Smith strain is a historical strain widely used for research
18 purposes in animal infection models for testing the therapeutic activity of antimicrobial
19 agents. We found that it displayed higher sensitivity towards lysocin E, a menaquinone (MK)
20 targeting antibiotic, compared to other *S. aureus* strains. Therefore, we further explored the
21 mechanism of this hypersensitivity.

22 **Methods:** MK production was analyzed by high-performance liquid chromatography and
23 mass spectrometric analysis. *S. aureus* Smith genome sequence was completed using a hybrid
24 assembly approach, and the MK biosynthetic genes were compared with other *S. aureus*
25 strains. The *hepT* gene was cloned and introduced into *S. aureus* RN4220 strain using phage
26 mediated recombination, and lysocin E sensitivity was analyzed by the measurement of
27 minimum inhibitory concentration and colony-forming units.

28 **Results:** We found that Smith strain produced MKs with the length of the side chain ranging
29 between 8 – 10, as opposed to other *S. aureus* strains that produce MKs 7 – 9. We revealed
30 that Smith strain possessed the classical pathway for MK biosynthesis like the other *S. aureus*.
31 HepT, a polyprenyl diphosphate synthase involved in chain elongation of isoprenoid, in
32 Smith strain was unique with a Q25P substitution. Introduction of *hepT* from Smith to
33 RN4220 led to the production of MK-10 and an increased sensitivity towards lysocin E.

34 **Conclusions:** We found that HepT was responsible for the definition of isoprenoid chain
35 length of MKs and antibiotic sensitivity.

36

37 **Introduction**

38 Menaquinone (MK), found in the cytoplasmic membrane, is an essential component of the
39 electron transport chain in Gram-positive bacteria. Apart from respiration, it plays vital roles
40 in oxidative phosphorylation and the formation of transmembrane potential. Given the
41 importance of MK in cellular survival, MK and its biosynthesis has been extensively
42 studied.¹⁻³ It has been shown that MK analogs inhibit the bacterial growth⁴ and several
43 enzymes involved in MK biosynthesis such-as isoprenoid precursor;⁵ naphthoquinone;⁶ and
44 incorporation of the isoprenoid side chain to naphthoquinone moiety⁷ can independently be
45 targeted for antimicrobial agent discovery against Gram-positive and acid-fast microbes.
46 Recently, we reported that lysocin E, a non-ribosomally synthesized peptide^{8,9} produced by
47 *Lysobacter* sp. RH2180-5, directly targets MK in the bacterial membrane exerting rapid and
48 potent bactericidal activity.¹⁰

49
50 MK is a 2-methyl-1,4-naphthoquinone with an isoprenoid side chain attached at the 3-
51 position. MK is generally referred to as MK-n, where n denotes the number of isoprenoid
52 units between 4 and 13 attached to the naphthoquinone core. The units of isoprene in the
53 MKs differ among different species and sometimes even within the same species.¹¹ The
54 difference in MK isoprenoid chain formed a basis of bacterial chemotaxonomic identification
55 in pre genomic era.¹²

56
57 *Staphylococcus aureus* is a human commensal and an opportunistic pathogen responsible for
58 a large number of hospitalization and deaths. Global spread and rise of methicillin-resistant^{13,}
59 ¹⁴
60 and vancomycin-resistant *S. aureus* strains¹⁵⁻¹⁷ have added the burden to health-care systems.
61 *S. aureus* uses MKs with the length of the side chain ranging between 7 – 9, where MK-8 is

the most predominant.¹² *S. aureus* strain Smith, isolated in 1930, is widely used in the laboratory for the development of mouse infection model as it displays a high degree of virulence against mouse model.¹⁸ Previously, we found that it displayed a higher susceptibility towards menaquinone targeting antibiotic- lysocin E.¹⁰ This led to speculation that MK biosynthetic machinery in *S. aureus* Smith might be different from other *S. aureus*. In this study, we report the complete genome sequence, MK analysis of *S. aureus* Smith and the factor responsible for its hypersensitivity towards lysocin E. To the best of our knowledge, this is the first report of the identification of *S. aureus* strain producing MK-10, and the involvement of a single substitution in HepT for MK-10 production and sensitivity towards antibiotic.

Materials and Methods

Microorganisms and culture conditions

The bacterial strains and plasmids used in this study are summarized in **Table 1**. *S. aureus* strains were routinely grown on tryptic soy broth, and *Escherichia coli* was grown on Luria-Bertani medium. Antibiotics were supplemented to the medium as required.

Table 1: Bacterial strains and plasmids used in this study

Strain/Plasmid	Details/Source
<i>Staphylococcus aureus</i>	
Smith	Isolated in 1930, ¹⁸ obtained from ATCC13709
RN4220	Restriction deficient strain, laboratory stock
Newman	Isolated in 1952, ¹⁹ laboratory stock
NCTC8325-4	Parent strain of RN4220, laboratory stock
JE2	USA300 strain obtained from BEI Resources
MRSA4	Clinical isolate ^{20, 21}

71101	Clinical isolate ²²
NCTC5663	Public Health England
<i>Escherichia coli</i> HST08	Competent cells for routine cloning from Takara
pND50-pfbaA	pND50 with <i>fbaA</i> promoter inserted in EcoRI/BamHI site ²³
pND50-pfbaA-hepT _{Smith}	hepT _{Smith} in pND50-pfbaA
pND50-pfbaA-hepT _{RN4220}	hepT _{RN4220} in pND50-pfbaA

79

80 **Table 2: Primers used to amplify *hepT* gene**

Primer	Sequence 5'-3' (underline indicate the restriction site)
BamF	CGCGGATCCATGAACAATGAAATTAAGAA
SalR1	ACGCGTCGACAATACTATGTGTTTCTTGAC
SalR2	ACGCGTCGACCTACGTGTTTCTTGAACCCA

81

82 **Whole-genome sequencing, assembly and comparative genomic analysis**

83 The complete genome of *S. aureus* Smith was sequenced using hybrid genome assembly as
84 explained previously²⁴⁻²⁶ using 1 µg and 100 ng of genomic DNA for Oxford Nanopore
85 MinION and ThermoFisher Ion PGM, respectively. The assembled genome was annotated
86 using the NCBI Prokaryotic Genome Annotation Pipeline. The draft genome of *S. aureus*
87 71101 was obtained by Illumina sequencing.²² The complete genome sequences of 324 *S.*
88 *aureus* strains were obtained from NCBI GenBank, and amino acid sequences of MK
89 biosynthetic genes were obtained using BLAST search.

90

91 ***hepT* cloning and heterologous expression:**

92 The *hepT* gene from *S. aureus* was amplified using the primer sets BamF vs SalR1 and BamF
93 vs SalR2 for Smith and RN4220 strains, respectively (**Table 2**). The BamHI SalI digested

94 PCR product was then ligated to pND50-*pfbaA* vector²³ digested with the same enzymes to
95 construct pND50-*pfbaA-hepT*_{Smith} and pND50-*pfbaA-hepT*_{RN4220}, respectively. The ligated
96 plasmid was then transformed to *Escherichia coli* HST08 (Takara Bio) and selected on
97 chloramphenicol plates. The strains with correct sequences were selected for transformation
98 into electrocompetent *S. aureus* RN4220. Insertion in the RN4220 strain was then confirmed
99 by PCR.

100

101 **Menaquinone extraction and HPLC analysis**

102 *S. aureus* strains were cultured overnight in 5 mL TSB supplemented with antibiotics as
103 required in a shaking incubator maintained at 37°C. The full growth was then diluted 100-
104 fold in the 5 mL TSB medium without antibiotics and incubated in the same shaker for 16
105 hours. A 300 µL of the culture broth was extracted twice with 1.5 mL of hexane 5: ethanol 2.
106 The supernatant was pooled, dried *in-vacuo*, dissolved in 200 µL ethanol and 80 µL of it was
107 analyzed using a Waters Alliance high-performance liquid chromatography (HPLC) system
108 equipped with a Senshu Pak PEGASIL ODS SP100 column (4.6φ x 250 mm) maintained at
109 40°C. After the application of the sample to the column equilibrated with 1 mL·min⁻¹ of
110 20% diisopropyl ether in methanol, the column was eluted with the same solvent. Detection
111 was made using a fluorescent detector using wavelengths 320 and 430 nm for excitation and
112 emission, respectively, after post-column reduction using a platinum column.

113

114 **High resolution mass spectrometric analysis**

115 High resolution mass spectrometric analysis was performed on a UPLC/MS system using a
116 Waters Acquity UPLC consisting of 2.1 x 50 mm Acquity UPLC® BEH C18 1.7 µm column.
117 After the injection of the sample to the column equilibrated with 0.3 mL·min⁻¹ of 100%
118 methanol, the eluate was continuously applied to a Waters Xevo G2-XS QToF mass

spectrometer. The data at the mass range of 100 – 1700 Da were collected in ESI positive mode using a source capillary voltage of 2.00 kV. The data were obtained using MassLynx 4.1 (Waters Milford, MA, USA) and analyzed by UNIFI Scientific Information System (Waters).

Lysocin E susceptibility

Clinical and Laboratory Standards Institute broth microdilution method was used to determine the minimum inhibitory concentrations (MIC).²⁷ Briefly, serial dilutions of lysocin E were prepared in cation-adjusted Mueller-Hinton Broth (Difco, Franklin Lakes, NJ, USA) and a 100 µL aliquot was then dispensed to each well of a 96-well plate. Inoculum containing approximately 1×10^6 colony forming units (CFU)/mL of bacteria was prepared from *Staphylococci* colonies grown at 37°C on Tryptic Soy Broth (Difco) agar plates. 10 µL of it was added to each well of the 96-well plate and incubated at 37°C for 18 h. The minimum concentration that inhibited the growth of bacteria was considered as the MIC value.

Viability of *S. aureus* upon treatment with lysocin E was determined as described previously^{21, 28} following NCCLS protocol.²⁹ Briefly, the overnight full growth of *Staphylococci* was diluted 100 fold with 5 mL TSB and incubated at 37°C with shaking. After the OD₆₀₀ reached 0.1, 1 mL aliquot was collected and treated with 1 mg/L of lysocin E, and incubation was continued for 30 minutes. The number of the surviving bacteria was counted by spreading on Mueller Hinton agar plates. Untreated samples at time zero were considered as 100% and used to calculate percentage survival.

Results and Discussion:

Higher Sensitivity of *S. aureus* Smith towards lysocin E

Lysocin E (**Figure 1a**) is a recently discovered antibiotic effective against Gram-positive bacteria that utilize MK for respiration.^{10, 30} Lysocin E has a potent and rapid bactericidal activity. It has a minimum inhibitory concentration (MIC) value of 4 mg/L against most of the laboratory *S. aureus* strains, which we tested, except for Smith strain, against which lysocin E consistently displayed an MIC value of 2 mg/L (**Figure 1b**). We further found a more potent bactericidal activity of lysocin E against Smith compared to Newman and JE2 strains (**Figure 1c**), suggesting its hypersensitive nature. As lysocin E targets MK,¹⁰ and *S. aureus* has MK as the sole quinone known to be utilized for respiration,³¹ we speculated that the MKs in Smith strain could be different from other *S. aureus* strains. However, there is no study about the type, content, and biosynthesis of MKs in *S. aureus* Smith. Therefore, we extracted MKs from the overnight cultures of the *S. aureus* Smith, Newman, and JE2 strains and analyzed by HPLC. Consistent with the previous report,³² Newman strain mainly produced MK-7 and MK-8, MK-8 being the most abundant, and trace amounts of MK-9. While MK production in JE2 was similar to that of Newman strain, Smith strain mainly produced MK-8 and MK-9, with MK-9 being the most abundant, and there appeared an undefined peak at the retention time of 34 minutes (**Figure 2a, b**). We then extracted MKs from a 50-mL volume of culture and separately collected each peak and analyzed by high-resolution mass spectrometry. We found that the peaks were 739.5449, 807.6043 and 875.6648 corresponding with $[M+Na]^+$ of MK-8, MK-9, and MK-10, respectively (**Figure 2c**). The undefined peak was thus identified as MK-10. Therefore, as opposed to the major quinone MK-8 in *S. aureus*,¹² Smith strain produced MK-9 predominantly. In addition, Smith strain produced MK-10, an MK that has not been reported in *S. aureus*. These results suggested that longer chain MKs in Smith strain might be responsible for its hypersensitivity towards lysocin E. Previously we found that *S. aureus* strains with mutation and/or deletions

in the genes involved in MK biosynthesis were resistant to lysocin E¹⁰ suggesting that analysis of MK biosynthetic genes in Smith would give an insight upon its hypersensitivity.

Figure 1: Lysocin E and its antimicrobial activity. (a) Chemical structure of lysocin E. (b) Minimum inhibitory concentrations of lysocin E against various *S. aureus*. MIC was determined by broth microdilution assay and represented as the median value obtained from 10 experiments. (c) Bactericidal activity of lysocin E. *S. aureus* strains were treated with 1 mg/L lysocin E for 30 minutes, and bacterial viability was determined. Triplicate data are represented as mean $\pm$ SEM and statistical analysis was performed by one-way ANOVA using Dunnett's multiple comparison test in GraphPad Prism. The asterisk indicates a *p*-value of <0.0001.

Figure 2: Analysis of MKs from *S. aureus*. (a) Chemical structure of MK-n and calculated exact mass of MK-8, 9, and 10 in positive ion analysis. (b) Analysis of MK extract from *S. aureus* Smith, Newman, and JE2. (c) High-resolution mass spectrometric analysis of peaks that appeared in Smith at 19, 25 and 34 minutes.

Analysis of MK biosynthetic pathway in *S. aureus* Smith

The ability of the Smith strain to produce MK-10 and an association of mutations in MK biosynthetic genes with lysocin E resistance¹⁰ triggered us to analyze the MK biosynthetic pathway of this strain so that we could identify the genetic basis of this unique feature. We obtained the complete genome sequence of the Smith strain using a hybrid Ion PGM and Nanopore MinION sequencing approach^{24, 26}. We performed a BLAST search against the genes involved in MK biosynthetic pathway. We found that the Smith strain harbored orthologs of all the genes involved in the classical pathway (**Figure 3**). We further aligned 11

195 MK biosynthetic enzymes among Newman, JE2 and Smith strains to find that Newman and
196 JE2 shared an end to end sequence identity in all the enzymes, while Smith strain had amino
197 acid substitution(s) in enzymes except MenA, MenG, and MenI (**Figure 3, Supplementary**
198 **Figure S1**).

199
200 Among the Smith MK biosynthetic enzymes that harbored amino acid substitution(s), the
201 majority were involved in the formation of 1,4-dihydroxy-2-naphthoate. Among the enzymes
202 involved in isoprenoid side chain biosynthesis, IspA (CFC57_08195) and HepT
203 (CFC57_07900) had 2, and 3, amino acid substitutions, respectively. IspA is predicted to be
204 involved in the formation of Farnesyl-PP, and HepT is predicted to be involved in the
205 condensation of Isopentenyl-PPs and Farnesyl-PPs, resulting in the formation of all-trans-
206 polyprenyl-PP. Based on this, we speculated that Smith HepT (HepT_{Smith} now onwards)
207 might be involved in the formation of longer chain polyprenyl-PPs to be attached to 1,4-
208 dihydroxy-2-naphthoate by MenA (CFC57_05630).

Figure 3: The classical MK biosynthetic pathway in *S. aureus* Smith. The highlighted enzymes have an end to end sequence identity between *S. aureus* Smith, JE2 and Newman strains.

Analysis of Staphylococcal HepT involved in polyprenyl diphosphate biosynthesis

We then analyzed the HepT sequence of all *S. aureus* strains whose complete genome sequence was available in NCBI. We focused on three substitutions (Pro-25, Leu-170, and Asp-288) that were different in Smith strain from Newman and JE2 strains (**Figure 4a**) and found that the HepT from 325 *S. aureus* strains could be categorized to five types which we named type 1 to type 5. Type 1 – 4 were present in at least 10 strains while type 5 was unique for Smith strain with Pro-25 (**Figure 4b**). Among these, we analyzed the MK content from strains harboring four available types of HepT and found that only Smith could produce MK-10 (**Figure 4c**). This result suggests that Pro-25 of HepT_{Smith} could be responsible for longer chain MK biosynthesis.

Figure 4. Analysis of Staphylococcal HepTs (a) Alignment of HepT from strains Smith, NCTC5663, 71101, and Newman. (b) Five types of *S. aureus* based on the position of amino acids at 25, 170, and 288 in the HepT sequence. Numbers in parenthesis indicate the number of strains in each type. Type 5 only contained Smith strain. (c) MK content of representative *S. aureus* strains to harbor four HepT types.

HepT_{Smith} is involved in chain length determination of MK

To confirm the role of HepT_{Smith} in longer chain MK biosynthesis, we cloned the *hepT* gene from the Smith strain and expressed it under the control of the constitutive expression promoter.²³ The plasmid thus obtained was introduced into the restriction deficient strain *S. aureus* RN4220. We also cloned the *hepT* gene from the RN4220 strain and introduced it into the RN4220 strain. We compared the MK production among Smith strain, RN4220 with empty vector, *hepT*_{Smith}, and *hepT*_{RN4220}. While the production of shorter chain MKs (MK-7 and MK-8) were similar in all the transductants, the introduction of *hepT*_{Smith} in RN4220

240 resulted in significantly higher production of MK-9 and the appearance of MK-10 (**Figure**
 241 **5a-c**). RN4220 harboring empty vector or *hepT*_{RN4220} predominantly produced MK-7 and
 242 MK-8, with a trace amount of MK-9, and the MK pattern was indifferent from that of the
 243 wild type strain (**Figure 5a-c**). These results suggest that HepT_{Smith} is responsible for the
 244 biosynthesis of longer chain MKs.

Figure 5. Analysis of MKs from *S. aureus* RN4220 with heterologously expressed HepT.

(a) Representative HPLC chromatograms. **(b)** Peak area of MK-7 and MK-8. **(c)** Peak area of MK-9 and MK-10. Data are from three independent experiments and represented as mean ± SEM. Statistical analysis was performed by one-way ANOVA using Dunnett's multiple comparison test in GraphPad Prism, and a *p*-value less than 0.05 was considered significant. ns: non-significant. # indicates an undetectable amount of MK-10.

Longer chain MKs are responsible for hypersensitivity to lysocin E

The hypersensitivity of Smith strain towards lysocin E, the presence of MK-10 in Smith strain, its unique HepT, and evidence showing the involvement of HepT_{Smith} in MK-10 production led us further to explore the role of HepT_{Smith} in lysocin E sensitivity. To elucidate this, we compared the viability of Smith and RN4220 strains harboring the empty vector and HepT_{Smith} upon treatment with 1 mg/L of lysocin E to find that a 30 minutes treatment drastically reduced the number of viable bacteria (**Figure 6**). Furthermore, Smith and RN4220 expressing HepT_{Smith} were hypersensitive to lysocin E treatment, suggesting that increased production of MKs harboring longer isoprenoid side chain might be responsible for the phenomena.

Figure 6. Survival of *S. aureus* in the presence of lysocin E. Exponentially growing bacteria were treated with 1 mg/L of lysocin E for 30 min, and the colony-forming units were counted. Triplicate data are represented as mean $\pm$ SEM. Statistical analysis was performed by one-way ANOVA using Dunnett's multiple comparison test in GraphPad Prism, and the asterisk indicates a *p*-value of <0.0001 .

In addition to MK biosynthesis, isoprenoids are critical for the biosynthesis of membrane lipids, carotenoids, sterols, and other components of the bacterial cell wall.³³ Isopentenyl-PP, one of the substrates of HepT and the starting molecule for other isoprenoid biosynthesis, is synthesized either via 2-C-methyl-D-erythritol-4-phosphate (MEP) and/or mevalonate pathway.^{34, 35} The enzymes of the MEP pathway have been used as targets for antibiotic discovery against microbes that harbor the MEP pathway.^{5, 36} Given that *S. aureus* relies on the mevalonate pathway,³⁷ HepT or other enzymes from this pathway can be targeted for the antistaphylococcal drug development.^{38, 39}

In summary, we completed the genome sequence of *S. aureus* Smith and performed the genomic analysis of the MK biosynthetic pathway to show that a classical pathway for MK biosynthesis is present in this strain. We demonstrated that Pro-25 substitution in HepT was responsible for longer chain MK biosynthesis, and this was associated with hypersensitivity towards lysocin E. This indicated that lysocin E might disrupt the bacterial membranes containing longer chain MKs more efficiently which requires further analysis. To the best of our knowledge, this is the first report of the identification of *S. aureus* strain producing MK-10.

Acknowledgements

The JE2 strain was provided by the Network on Antimicrobial Resistance in *Staphylococcus aureus*, distributed by BEI Resources, National Institute of Allergy and Infectious Diseases, National Institutes of Health. We thank Ms. Maeda from Genome Pharmaceuticals Institute Co., Ltd. for technical assistance.

Funding

This work was supported by the Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (grant numbers JP15H05783 to K. S., JP19K16653 to A. P., JP19K07140 to H. H., and JP17F17421 fellowships to S. P. and K. S.). S. P. acknowledges funding received from the Institute of Fermentation, Osaka, Japan, and Tokyo Biochemical Research Foundation.

Transparency declarations:

None to declare.

Supplementary data

Supplementary figure 1 is available online.

Data Availability

The complete genome assembly of *S. aureus* Smith has been deposited at DDBJ/ENA/GenBank with accession numbers: CP029751 and CP029750, for chromosome and plasmid pSS41, respectively. The BioProject accession number for this project is PRJNA392199.

References

1. Paudel A, Hamamoto H, Panthee S et al. Menaquinone as a potential target of antibacterial agents. *Drug Discoveries & Therapeutics* 2016; **10**: 123-8.
2. Hiratsuka T, Furihata K, Ishikawa J et al. An alternative menaquinone biosynthetic pathway operating in microorganisms. *Science* 2008; **321**: 1670-3.
3. Seto H, Jinnai Y, Hiratsuka T et al. Studies on a new biosynthetic pathway for menaquinone. *J Am Chem Soc* 2008; **130**: 5614-5.
4. Schlievert PM, Merriman JA, Salgado-Pabón W et al. Menaquinone analogs inhibit growth of bacterial pathogens. *Antimicrob Agents Chemother* 2013; **57**: 5432-7.
5. Jomaa H, Wiesner J, Sanderbrand S et al. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. *Science* 1999; **285**: 1573.
6. Fang M, Toogood RD, Macova A et al. Succinylphosphonate esters are competitive inhibitors of MenD that show active-site discrimination between homologous α -ketoglutarate-decarboxylating enzymes. *Biochemistry* 2010; **49**: 2672-9.
7. Dhiman RK, Mahapatra S, Slayden RA et al. Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence. *Mol Microbiol* 2009; **72**: 85-97.

- 328 8. Panthee S, Hamamoto H, Suzuki Y et al. In silico identification of lysocin
329 biosynthetic gene cluster from *Lysobacter* sp. RH2180-5. *J Antibiot* 2017; **70**: 204-7.
- 330 9. Panthee S, Hamamoto H, Paudel A et al. *Lysobacter species*: a potential source of
331 novel antibiotics. *Arch Microbiol* 2016; **198**: 839-45.
- 332 10. Hamamoto H, Urai M, Ishii K et al. Lysocin E is a new antibiotic that targets
333 menaquinone in the bacterial membrane. *Nat Chem Biol* 2015; **11**: 127-33.
- 334 11. Kurosu M, Eeshwaraiah B. Vitamin K2 in electron transport system: are enzymes
335 involved in vitamin K2 biosynthesis promising drug targets? *Molecules* 2010; **15**: 1531-53.
- 336 12. Collins MD, Jones D. Distribution of isoprenoid quinone structural types in bacteria
337 and their taxonomic implications. *Microbiol Rev* 1981; **45**: 316-54.
- 338 13. Mostofsky E, Lipsitch M, Regev-Yochay G. Is methicillin-resistant *Staphylococcus*
339 *aureus* replacing methicillin-susceptible *S. aureus*? *J Antimicrob Chemother* 2011; **66**: 2199-
340 214.
- 341 14. Moellering RC, Jr. MRSA: the first half century. *J Antimicrob Chemother* 2011; **67**:
342 4-11.
- 343 15. Panthee S, Hamamoto H, Paudel A et al. Genomic analysis of vancomycin-resistant
344 *Staphylococcus aureus* VRS3b and its comparison with other VRSA isolates. *Drug Discov*
345 *Ther* 2017; **11**: 78-83.
- 346 16. Panthee S, Paudel A, Hamamoto H et al. Draft genome sequence of the vancomycin-
347 resistant clinical isolate *Staphylococcus aureus* VRS3b. *Genome Announc* 2017; **5**: e00452-
348 17.
- 349 17. McGuinness WA, Malachowa N, DeLeo FR. Focus: infectious diseases: vancomycin
350 resistance in *Staphylococcus aureus*. *YJBM* 2017; **90**: 269-81.
- 351 18. Hunt GA, Moses AJ. Acute infection of mice with Smith Strain of *Staphylococcus*
352 *aureus*. *Science* 1958; **128**: 1574.
- 353 19. Duthie ES, Lorenz LL. Staphylococcal Coagulase: Mode of Action and Antigenicity.
354 *Microbiology* 1952; **6**: 95-107.
- 355 20. Paudel A, Hamamoto H, Kobayashi Y et al. Identification of novel
356 deoxyribofuranosyl indole antimicrobial agents. *J Antibiot* 2012; **65**: 53-7.
- 357 21. Paudel A, Kaneko K, Watanabe A et al. Structure-activity relationship study of novel
358 iminothiadiazolo-pyrimidinone antimicrobial agents. *J Antibiot* 2013; **66**: 663-7.
- 359 22. Uhlemann A-C, McAdam PR, Sullivan SB et al. Evolutionary dynamics of pandemic
360 methicillin-Sensitive *Staphylococcus aureus* ST398 and its international spread via routes of
361 human migration. *mBio* 2017; **8**: e01375-16.
- 362 23. Paudel A, Hamamoto H, Panthee S et al. Large-scale screening and identification of
363 novel pathogenic *Staphylococcus aureus* genes using a silkworm infection model. *J Infect*
364 *Dis* 2020.
- 365 24. Panthee S, Hamamoto H, Ishijima SA et al. Utilization of hybrid assembly approach
366 to determine the genome of an opportunistic pathogenic fungus, *Candida albicans* TIMM
367 1768. *Genome Biol Evol* 2018; **10**: 2017-22.
- 368 25. Paudel A, Panthee S, Hamamoto H et al. GPI0363 inhibits the interaction of RNA
369 polymerase with DNA in *Staphylococcus aureus*. *RSC Adv* 2019; **9**: 37889-94.
- 370 26. Panthee S, Paudel A, Blom J et al. Complete Genome Sequence of *Weissella*
371 *hellenica* 0916-4-2 and Its Comparative Genomic Analysis. *Front Microbiol* 2019; **10**.
- 372 27. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial
373 susceptibility tests for bacteria that grow aerobically; approved standard—ninth edition
374 (CLSI document M07–A9). Wayne, PA: Clinical and Laboratory Standards Institute, 2012.
- 375 28. Paudel A, Hamamoto H, Panthee S et al. A novel spiro-heterocyclic compound
376 identified by the silkworm infection model inhibits transcription in *Staphylococcus aureus*.
377 *Front Microbiol* 2017; **8**: 712.

29. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents; approved guideline (NCCLS document M26-A). Wayne, PA: National Committee for Clinical Laboratory Standards, 1999.
30. Itoh H, Tokumoto K, Kaji T et al. Development of a high-throughput strategy for discovery of potent analogues of antibiotic lysocin E. *Nat Commun* 2019; **10**: 2992.
31. Bentley R, Meganathan R. Biosynthesis of vitamin K (menaquinone) in bacteria. *Microbiol Rev* 1982; **46**: 241-80.
32. Wakeman CA, Hammer ND, Stauff DL et al. Menaquinone biosynthesis potentiates haem toxicity in *Staphylococcus aureus*. *Mol Microbiol* 2012; **86**: 1376-92.
33. Oldfield E. Targeting isoprenoid biosynthesis for drug discovery: bench to bedside. *Acc Chem Res* 2010; **43**: 1216-26.
34. Lange BM, Rujan T, Martin W et al. Isoprenoid biosynthesis: The evolution of two ancient and distinct pathways across genomes. *Proc Natl Acad Sci U S A* 2000; **97**: 13172.
35. Khalid A, Takagi H, Panthee S et al. Development of a terpenoid-production platform in *Streptomyces reveromyceticus* SN-593. *ACS Synth Biol* 2017; **6**: 2339-49.
36. Shigi Y. Inhibition of bacterial isoprenoid synthesis by fosmidomycin, a phosphonic acid-containing antibiotic. *J Antimicrob Chemother* 1989; **24**: 131-45.
37. Balibar CJ, Shen X, Tao J. The mevalonate pathway of *Staphylococcus aureus*. *J Bacteriol* 2009; **191**: 851-61.
38. Desai J, Liu Y-L, Wei H et al. Structure, function, and inhibition of *Staphylococcus aureus* heptaprenyl diphosphate synthase. *ChemMedChem* 2016; **11**: 1915-23.
39. Matsumoto Y, Yasukawa J, Ishii M et al. A critical role of mevalonate for peptidoglycan synthesis in *Staphylococcus aureus*. *Sci Rep* 2016; **6**: 22894.